Taxus Cardium Pharmaceuticals Group, Inc. manages a portfolio of medical technologies in the United States. The company engages in the development and commercialization of Generx, an angiogenic gene therapy product candidate that is in Phase III clinical trial for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease. It also provides Excellagen technology platform, a FDA-approved flowable dermal matrix for advanced wound care treatment, as well as serves as a delivery platform for small molecule drugs, proteins, and biologics. In addition, the company develops a medical data analytics technology platform, which offers products for the life insurance and healthcare sectors. The company was formerly known as Cardium Therapeutics, Inc. and changed its name to Taxus Cardium Pharmaceuticals Group, Inc. in March 2014. Taxus Cardium Pharmaceuticals Group, Inc. was founded in 2003 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-436-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees6
Next Earnings DateN/A
OptionableNot Optionable
Gene Biotherapeutics (OTCMKTS:CRXM) Frequently Asked Questions
What is Gene Biotherapeutics' stock symbol?
Gene Biotherapeutics trades on the OTCMKTS under the ticker symbol "CRXM."
Has Gene Biotherapeutics been receiving favorable news coverage?
Media coverage about CRXM stock has been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gene Biotherapeutics earned a news sentiment score of -3.9 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Gene Biotherapeutics.
Who are some of Gene Biotherapeutics' key competitors?
What other stocks do shareholders of Gene Biotherapeutics own?
Who are Gene Biotherapeutics' key executives?
Gene Biotherapeutics' management team includes the folowing people:
- Mr. Christopher J. Reinhard, Co-Founder, Chairman, CEO, Pres & Treasurer (Age 65)
- Mr. Jiayue Zhang, Exec. Chairman (Age 61)
- Mr. Duane Linstrom, Gen. Counsel
- Dr. Gabor M. Rubanyi, Chairman of Scientific Advisory Board & Chief Scientific Officer (Age 72)
- Mr. Kelly D. Scott, VP of Bus. Devel. of Medtech Bus. Unit and EVP of Inner Cool Therapies Inc (Age 63)
How do I buy shares of Gene Biotherapeutics?
Shares of CRXM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Gene Biotherapeutics' stock price today?
One share of CRXM stock can currently be purchased for approximately $0.14.
How big of a company is Gene Biotherapeutics?
What is Gene Biotherapeutics' official website?
How can I contact Gene Biotherapeutics?
Gene Biotherapeutics' mailing address is 11568 SORRENTO VALLEY ROAD SUITE 14, SAN DIEGO CA, 92121. The company can be reached via phone at 858-436-1000 or via email at [email protected]
MarketBeat Community Rating for Gene Biotherapeutics (OTCMKTS CRXM)
MarketBeat's community ratings are surveys of what our community members think about Gene Biotherapeutics and other stocks. Vote "Outperform" if you believe CRXM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRXM will underperform the S&P 500 over the long term. You may vote once every thirty days.
